Clinical Trials Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd

Total 652 results

Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

EGFR Positive Non-small Cell Lung Cancer

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

China
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (ALTER-L013)

NSCLC

China
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Solid Tumor | Neuroblastoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Advanced Solid Tumor | Liposarcoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-2449 in Patients With Advanced Solid Tumors

Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Malignant Pleural Mesothelioma | Advanced Solid Cancer

China
Zhejiang University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients (ALTER-C-002)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Colonic Diseases | Intestinal Diseases | Colorectal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Colorectal Cancer | RAS and BRAF Wild-type

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Terminated

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Small Cell Lung Cancer and Other Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fudan University

Unknown

A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics

Solid Tumor

China
Beijing Continent Pharmaceutical Co, Ltd.
Shanghai Genomics, Inc.; GNI-EPS Pharmaceuticals, Inc. (GNI Group)

Unknown

Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)

China
Beijing Continent Pharmaceutical Co, Ltd.
Shanghai Genomics, Inc.; GNI-EPS Pharmaceuticals, Inc. (GNI Group)

Unknown

Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury

Radiation Pneumonitis
Second Affiliated Hospital, School of Medicine,...
SICHUAN CREDIT PHARMACEUTICAL CO., LTD.

Not yet recruiting

TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）

Migraine Without Aura | Migraine With Aura

China
Sichuan Huiyu Pharmaceutical Co., Ltd
The First Hospital of Jilin University; Suzhou Guochen Biotek Co., Ltd.; Boji... and other collaborators

Completed

Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia

Iron Deficiency | Anaemia

China
Qiang Fu
Yangtze River Pharmaceutical Group Co., Ltd.

Not yet recruiting

Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules (CRF)

Cancer-related Fatigue
Yooyoung Pharmaceutical Co., Ltd.
Opera CRO, a TIGERMED Group Company

Not yet recruiting

Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of ORTHIX PLUS

Osteoarthritis, Knee | Degenerative Joint Disease of Knee
Yooyoung Pharmaceutical Co., Ltd.
Opera CRO, a TIGERMED Group Company

Not yet recruiting

Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of HYALEXO

Osteoarthritis | Degenerative Joint Disease
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Non-squamous Cell Non-Small Cell Lung Cancer

China
Guizhou Bailing Group Pharmaceutical Co Ltd
China-Japan Friendship Hospital

Completed

Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule (TNTL)

Accidental Exposure While Preparing Drug for Administration

China
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (FAITH)

Hepatocellular Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

Esophageal Neoplasms

China
Chinese PLA General Hospital
Jiangsu Suzhong Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease

Chronic Kidney Disease

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Medical University

Completed

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (ALTN)

Advanced Cancer

China
Zhejiang Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Innovent Biologics (Suzhou)...

Unknown

The Efficacy and Safety of Antinib Hydrochloride Combined With Sindilumab in Advanced NSCLC Patients

NSCLC

China
Pharmaceutical Factory of Chengdu HuaSun Group...
West China Second University Hospital; Sichuan University

Completed

A Bioequivalence Study of Sanchi-Tongshu Capsule (Enteric Coated Pellets)

Healthy

China
Henan Provincial People's Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC (ALTER-L025)

Non-squamous Cell Non-Small Cell Lung Cancer

China
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (ALTER-HN005)

Nasopharyngeal Neoplasms
Beijing Tiantan Hospital
Tasly Pharmaceutical Group Co., Ltd; Beijing Neurosurgical Institute

Recruiting

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Peking Union Medical College Hospital
CSPC Ouyi Pharmaceutical Group Co., Ltd.

Not yet recruiting

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Cryptococcal Meningitis

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Henan Cancer Hospital
Rongchang Biopharmaceutical; Zhengda Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

HER2-positive Gastric Cancer | Advanced Gastric Carcinoma

China
Jiangxi Provincial Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients (ALTER-E005)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Carcinoma, Squamous Cell | Esophageal Neoplasms | Esophageal Diseases | Neoplasms, Squamous Cell | Esophageal Squamous Cell Carcinoma

China
Zhejiang Hisun Pharmaceutical Co. Ltd.
Opera CRO, a TIGERMED Group Company

Unknown

A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19

COVID-19

China, Germany, Romania
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Qilu Hospital of Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (ACDFNSNSCLC)

Non Small Cell Lung Cancer
Second Affiliated Hospital of Wenzhou Medical University
Wanbangde Pharmaceutical Group Co., LTD

Not yet recruiting

Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults

Pharmacokinetics
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Non Small Cell Lung Cancer

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib or Penpulimab in Combination With RAI for DTC

Thyroid Cancer

China
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Second Affiliated Hospital of Wenzhou Medical University
Wanbangde Pharmaceutical Group Co., LTD

Unknown

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)

Novel Coronavirus Pneumonia | 2019-nCoV

China
Chen Xiangmei
Jiangsu Suzhong Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy

IgA Nephropathy

China
Vall d'Hebron Institute of Oncology
Taisho Pharmaceutical Co., Ltd.; Roche Pharma AG; Iqvia Pty Ltd; Janssen, LP

Recruiting

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)

Advanced Solid Tumor

Spain, France, Germany, Netherlands, Sweden, United Kingdom, Italy
Japan Clinical Oncology Group
Taiho Pharmaceutical Co., Ltd.; Ministry of Health, Labour and Welfare, Japan; Yakult Honsha Co., LTD

Completed

A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer

Gastric Cancer

Japan
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Xianhai Mao
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (ALTER-H006)

Hepatocellular Carcinoma | Adjuvant Therapy

China
First Affiliated Hospital Xi'an Jiaotong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (ALTER-H-004)

Hepatocellular Carcinoma | Anlotinib | TACE

China

Clinical Trials Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations